Ibrutinib is a new drug being studied to treat myeloma and is a Bruton’s Tyrosine Kinase (BTK) Inhibitor. The drug targets BTK, an enzyme necessary for the development of fully functional B-cells. The BTK enzyme is known to be more prolific in cancerous B-cells. Malignant myeloma cells have increased BTK expression compared to non-malignant cells, so blocking BTK activity in myeloma has been shown to inhibit growth of tumors and release of osteoclast-derived tumor growth factors. Ibrutinib has been studied since the 1990’s and has been used in many clinical trial in the last few years.
A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)
The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:
There are 5 locations for this trial.
To find the clinical trial on SparkCures, click here: